Acelyrin reports Q2 EPS (86c), consensus (75c)

Reports cash, cash equivalents and short-term marketable securities totaled $635.2M at June 30 . The Company expects these to fund operations to mid-2027..”While today’s positive HS data and previously announced psoriatic arthritis PsA data support a path to approval for izokibep, we have determined that a program of this breadth and size is best brought to market by a larger organization with the resources and existing footprint in these indications,” said Mina Kim, Chief Executive O?cer of ACELYRIN. “We remain excited by the opportunity for lonigutamab to address unmet needs of patients with TED. Consistent with our commitment to disciplined capital allocation, we have decided to focus our e?orts toward rapidly advancing lonigutamab through late-stage development with our existing cash resources. Combined with a reduction in force, this strategic shift allows us to extend our cash runway to mid-2027 and fully fund both Phase 3 trials for lonigutamab.”